Nasdaq Vera News Today

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) saw strong trading volume on Thursday . 980,711 shares traded hands during trading, a decline of 21% from the previous session’s volume of 1,245,474 shares.The stock last traded at $43.49 and had previously closed at $41.62. Analysts Set New Price Targets A number of equities analysts have […]

Guggenheim reaffirmed their buy rating on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research report released on Friday, Benzinga reports. They currently have a $56.00 price target on the stock. Several other brokerages have also commented on VERA. Raymond James raised Vera Therapeutics from an outperform rating to a strong-buy rating and […]

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report)’s share price gapped down before the market opened on Monday after an insider sold shares in the company. The stock had previously closed at $37.52, but opened at $36.63. Vera Therapeutics shares last traded at $37.81, with a volume of 45,552 shares traded. Specifically, Director Maha Katabi […]

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CFO Sean Grant sold 99,828 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the completion of the transaction, the chief financial officer now directly owns 66,337 […]

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price objective boosted by Wedbush from $21.00 to $34.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a neutral rating on the stock. A number of other analysts also recently issued reports on the stock. Raymond James raised shares of Vera […]

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy […]

BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and...

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price target boosted by Wedbush from $16.00 to $21.00 in a research note published on Friday, Benzinga reports. The brokerage currently has a neutral rating on the stock. VERA has been the subject of several other reports. JPMorgan Chase & Co. dropped their price target on Vera […]

Vera Therapeutics (NASDAQ:VERA – Free Report) had its target price boosted by Wedbush from $16.00 to $21.00 in a report published on Friday morning, Benzinga reports. They currently have a neutral rating on the stock. VERA has been the subject of several other research reports. JPMorgan Chase & Co. dropped their price objective on shares […]

Vera Therapeutics (NASDAQ:VERA – Get Free Report) was upgraded by research analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a report issued on Friday, Benzinga reports. The firm currently has a $37.00 price objective on the stock, up from their previous price objective of $29.00. Raymond James’ price objective suggests […]